Condition: CAR T Cell Therapy · Systemic Lupus Erythematosus · BCMA · Sponsor: The Children's Hospital of Zhejiang University School of Medicine
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
This description comes directly from the study's public registry record.
Jianhua Mao, MD · 13516819071 · maojh88@zju.edu.cn
Xue He · 15088688407 · hexue1119@163.com
Always discuss trial participation with your own doctor first.
| hildren's Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06934447